BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $310.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 report.

The analyst quotes: "Beyond the financials, we are encouraged that key regulatory authorities accepted approval applications for tirzepatide as a novel treatment for diabetes—we still look to the obesity data later this year. In oncology, the company submitted the rolling NDA for pirtobrutinib in mantle cell lymphoma. Olumiant continues to be challenging with lack of alignment on a go forward plan for AD; and recent top-line data point to a no-go for the SLE indication. Still for 2022, we are focused on updates in Alzheimer’s disease (donanemab vs. Adu data) and updates on tirzepatide (obesity and T2D approval/launch), among others. All in this print is good enough to continue to support our positive view of the name. Reiterate Outperform."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $250.83 yesterday.